Long-term open-label response to atomoxetine in adult ADHD: Influence of sex, emotional dysregulation, and double-blind response to atomoxetine

ADHD Attention Deficit and Hyperactivity Disorders

Volumn 3, Issue 3, 2011, Pages 237-244

  Marchant, Barrie K ^a,b   Reimherr, Fred W ^a   Halls, Corinne ^a   Williams, Erika D ^a   Strong, Robert E ^a   Kondo, Douglas ^a   Soni, Poonam ^a   Robison, Reid J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

ADHD; Adult; Atomoxetine; Emotional dysregulation; Gender; Long term

Indexed keywords

ATOMOXETINE; PLACEBO;

ADULT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CANADA; CONNER ADULT ATTENTION DEFICIT DISORDER RATING SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG RESPONSE; EMOTIONAL DISORDER; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES; WENDER REIMHERR ADULT ATTENTION DEFICIT DISORDER SCALE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AFFECTIVE SYMPTOMS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS; TIME FACTORS;

EID: 80051947398     PISSN: 18666116     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-011-0054-2     Document Type: Article

References (22)

1. Adler LA, Spencer TJ, Milton DR et al (2005) Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66: 294-299.
2. Adler LA, Spencer TJ, Williams DW, et al (2008) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 248-253.
3. Adler LA, Spencer T, Brown TE et al (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29: 44-50.
4. Biederman J, Spencer TJ (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46: 1234-1242.
5. Biederman J, Spencer TJ, Wilens TE et al (2005) Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 10(Suppl 20): 16-25.
6. Biederman J, Ball SW, Monuteaux MC et al (2008) New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry 47: 426-434.
7. Conners CK, Erhardt D, Sparrow E (1999) Conners' adult ADHD rating scales (CAARS). Multi-Health Systems Inc, North Tonawanda.
8. Faraone SV, Biederman J (1998) Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 44: 951-958.
9. Marchant BK, Reimherr FW, Halls C et al (2010) OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study. Ann Clin Psychiatry 22: 196-204.
10. Michelson D, Allen AJ, Busner J et al (2002) Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901.
11. Michelson D, Adler L, Spencer T et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120.
12. Quinn PO (2008) Attention-deficit/hyperactivity disorder and its comorbidities in women and girls: an evolving picture. Curr Psychiatry Rep 10(5): 419-423.
13. Rasmussen K, Levander S (2009) Untreated ADHD in adults: are there sex differences in symptoms, comorbidity, and impairment? J Atten Disord 12(4): 353-360.
14. Reimherr FW, Marchant BK, Strong RE et al (2005) Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 58: 125-131.
15. Reimherr FW, Williams ED, Strong RE et al (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68(1): 93-101.
16. Robison RJ, Reimherr FW, Marchant BK et al (2008) Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 69: 213-221.
17. Rösler M, Fischer R, Ammer R et al (2009) A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259: 120-129.
18. Rösler M, Retz W, Fischer R et al (2010) Twenty-four-week treatment with extended release methylphenidate improved emotional symptoms in adult ADHD. World J Biol Psychiatry 11: 709-718.
19. Weisler RH, Biederman J, Spencer TJ et al (2005) Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 12(Suppl 20): 35-43.
20. Weisler R, Young J, Mattingly G et al (2009) Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 14: 573-585.
21. Wender PH (1995) Attention-deficit hyperactivity disorder in adults. Oxford University Press, New York.
22. Wender PH, Reimherr FW, Marchant BK et al (2011) One year trial of methylphenidate in adult ADHD. J Atten Disord 15: 36-45.